Barbara Wiseley-Cortland, APRN
Psychiatric/Mental Health, Adult · Cleveland, OHNPI 1720127137
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 41.3% of the total.
Across 38 payments — averaging $36.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$579
- Otsuka America Pharmaceutical, Inc.$213
- AbbVie$160
- E.r. Squibb & Sons, L.L.C.$140
- Alkermes, Inc.$138
- Neurocrine Biosciences, Inc.$61
- plus $110 from 4 others
What the payments were for
- Food & beverage$1,35297%
- Education$493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $579 |
| Otsuka America Pharmaceutical, Inc. | 6 | $213 |
| AbbVie | 4 | $160 |
| E.r. Squibb & Sons, L.L.C. | 2 | $140 |
| Alkermes, Inc. | 2 | $138 |
| Neurocrine Biosciences, Inc. | 3 | $61 |
| Lundbeck LLC | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,401 in reported general payments places this provider in the 65th percentile of 42 psychiatric/mental health, adult providers in Ohio.
See all psychiatric/mental health, adult providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buspirone Hcl | 15 | $131 |
| Pantoprazole Sodium | 11 | $46 |
| Escitalopram Oxalate | 11 | $40 |
| Atorvastatin Calcium | 11 | $38 |
| Trazodone Hcl | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health, adult in Cleveland
- James SrpCleveland$25
- Latrice WaddellToledo$33K
- David BinghamToledo$12K
- Shirley BuddingDayton$9K
- Joanne VaccaniCanton$8K
- Donna BeaumontAthens$7K
- Dawn GreskoMiddleburg Heights$5K
- Regina EngelCincinnati$5K
- Laura MoyerChesterland$4K
- Grace HerwigWestlake$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.